汉氏联合品牌怎么样 申请店铺

我要投票 汉氏联合在干细胞行业中的票数:164 更新时间:2025-04-04
汉氏联合是哪个国家的品牌?「汉氏联合」是 北京汉氏联合生物技术股份有限公司 旗下著名品牌。该品牌发源于北京,由创始人韩忠朝在2007-01-08期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力汉氏联合品牌出海!通过在本页面挂载汉氏联合品牌的产品链接和联系邮箱,可以提高汉氏联合产品曝光!跨境电商爆单神器,目前只要100元/年哦~

汉氏联合怎么样

北京汉氏联合生物技术股份有限公司(简称“汉氏联合”)成立于2007年,是国家认定的高新技术企业。作为干细胞产业领域的先锋企业,汉氏联合致力于人类生命健康发展,以干细胞再生医学技术为核心,逐步形成以围产期干细胞存储、细胞及再生医学技术开发、药物研发为主导的科技平台,以精准再生医学、健康管理、医院集团、教育培训、生物护肤及国际医疗旅游为主导的医疗健康平台,旨在打造干细胞再生医学全产业链闭环。

目前,汉氏联合已在全国发展布局19家子公司,2015年,集团在法国建立了首家海外子公司-法国汉氏联合(H&B France),成功跻身国际市场。汉氏联合集团聚集了一批国家级乃至国际级专家和科技人员,科研团队凭借强大的研发实力,自主研发几十项专利技术并多次创造行业记录,研究成果荣获国家科技进步一等奖和二等奖各1项、10余项省部级科技进步一等奖和二等奖。

自90年代至今,以董事长韩忠朝院士为代表的科研团队成功倡导三次围产期干细胞技术革命,成为国内甚至全球范围内围产期干细胞技术研发的风向标。汉氏联合集团在中国开创了同时可以保存多种胎盘组织源干细胞的干细胞银行,截至2019年,汉氏联合按各省市要求在北京、天津、山东、广东、福建、江西与贵州建设7家干细胞库。

一直以来,汉氏联合都专注于干细胞新药研发领域。2011年,汉氏联合集团在全球范围内率先发明以基于胎盘间充质干细胞移植治疗II型糖尿病技术,还开展了胎盘组织来源的造血干细胞的临床转化。基于汉氏联合的研发技术,共自主研发了10余款干细胞新药。2019年,集团自主研发的1类新药“人胎盘间充质干细胞凝胶”获得国家食品药品监督管理总局(NMPA)临床试验默示许可,这是全球第一款以活的胎盘间充质干细胞与生物材料混合制备的皮肤外用药物。此外,汉氏联合研发的注射用生物制品“注射用间充质干细胞(脐带)”新药也获NMPA受理;“高活性间充质干细胞注射液” I/IIa期于2019年获得法国药监局(ANSM)临床试验许可。

在精准再生医学领域,公司致力于干细胞再生医学、肿瘤细胞分型、遗传筛查、免疫细胞治疗、循环肿瘤细胞(CTC)和循环肿瘤DNA(ctDNA)等精准医学和临床转化医学的研究。汉氏联合借鉴美国梅奥医疗中心的经验,正在打造以医疗服务为中心的汉氏联合医学平台,包括生命科学院(本科院校)、三级医院、综合门诊部、体检中心、临检中心及互联网+医院。

汉氏联合集团以“干细胞再生医学技术产品”、“干细胞技术服务”以及“精准医疗服务”三大业务为核心板块,采用科学的资源整合、先进的运营模式、“以人为本”的价值理念,打造民族品牌的“产、学、研、医、养、美”联合体,引领再生医学产业,为人民提供优质的医疗健康服务。


Founded in 2007, Beijing Hanshi United Biotechnology Co., Ltd. (hereinafter referred to as "Hanshi united") is a high-tech enterprise recognized by the state. As a pioneer in the field of stem cell industry, Hans United is committed to the healthy development of human life. With stem cell regenerative medicine technology as the core, it has gradually formed a technology platform dominated by perinatal stem cell storage, cell and regenerative medicine technology development, and drug research and development, with precision regenerative medicine, health management, hospital group, education and training, biological skin care and international medical treatment Tourism as the leading medical and health platform aims to create a closed-loop of the whole industry chain of stem cell regenerative medicine. At present, Heinz Union has developed 19 subsidiaries in China. In 2015, the group established the first overseas subsidiary in France, H & bfrance, and successfully entered the international market. Hanshi United Group has gathered a group of national and even international experts and scientific and technological personnel. With strong R & D strength, the scientific research team independently researched and developed dozens of patented technologies and created industry records for many times. The research results have won the first and second prizes of national science and technology progress, respectively, and more than 10 provincial and ministerial science and technology progress first and second prizes. Since the 1990s, the research team, represented by academician Han Zhongchao, chairman of the board of directors, has successfully advocated three revolutions of perinatal stem cell technology, becoming the wind vane of research and development of perinatal stem cell technology at home and even around the world. Han's joint group has created a stem cell bank in China that can simultaneously store a variety of placenta derived stem cells. By 2019, Han's joint group has built seven stem cell banks in Beijing, Tianjin, Shandong, Guangdong, Fujian, Jiangxi and Guizhou according to the requirements of various provinces and cities. For a long time, Hamilton Union has been focusing on the research and development of new stem cell drugs. In 2011, Hans group took the lead in the world in inventing the technology of treating type II diabetes mellitus based on placental mesenchymal stem cell transplantation, and also carried out the clinical transformation of placental tissue-derived hematopoietic stem cells. Based on the joint research and development technology of Hans, more than 10 new stem cell drugs have been independently developed. In 2019, the group's 1 new drugs, "human placental mesenchymal stem cell gel", were granted the permission of the national food and Drug Administration (NMPA) clinical trial. This is the world's first skin topical drug produced by the combination of living placenta derived mesenchymal stem cells and biomaterials. In addition, the new drug "mesenchymal stem cells for injection (umbilical cord)" jointly developed by Hans has also been accepted by nmpa; the phase I / IIA of "highly active mesenchymal stem cells injection" has obtained the clinical trial license of ansm in 2019. In the field of precision regenerative medicine, the company is committed to stem cell regenerative medicine, tumor cell typing, genetic screening, immune cell therapy, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) and other precision medicine and clinical transformation medicine research. Han's experience from the Mayo Medical Center in the United States is building a medical center for the Han's joint medical platform, including the Life Sciences Academy (undergraduate), three level hospital, comprehensive outpatient department, physical examination center, clinical examination center and Internet plus hospital. Hanshi united group takes "stem cell regenerative medical technology products", "stem cell technology services" and "precision medical services" as its core businesses, adopts scientific resource integration, advanced operation mode and "people-oriented" value concept to build a national brand "production, learning, research, medicine, nutrition and beauty" consortium, leading the regenerative medical industry and serving the people Provide quality medical and health services.

本文链接: https://brand.waitui.com/c5adab6e2.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

日产撤回美国工厂减产计划 应对特朗普关税

日产汽车4日透露,撤回作为合理化措施之一、原定4月起实施的美国工厂减产计划,维持当前生产体制。鉴于美国特朗普政府对进口汽车加征关税的措施3日生效,此举旨在让不征收关税的本地生产保持规模。(新浪财经)

2小时前

机构:欧洲股市料小幅低开,美国关税继续拖累市场

预计欧洲股市今日开盘将小幅走低,此前美国总统特朗普宣布征收全面贸易关税,导致周四股市大幅下挫。据IG,预计欧洲斯托克600指数将低开0.15%;德国DAX指数和英国富时100指数预计将低开0.1%。投资者担心美国关税政策对全球经济的影响,此外,周五的注意力转向美国的就业数据。这将让人们初步了解美国关税政策宣布前的就业市场状况。投资者还在关注任何有关针对美国关税的反制措施的声明。丹麦银行的分析师在一份研究报告中称:“亚洲股市[周五]上午继续走低,欧洲和美国的股指期货也是如此。(新浪财经)

2小时前

美油跌至2023年5月以来最低水平

WTI原油期货跌至2023年5月以来最低水平,最低报65.2美元/桶,日内跌2.5%。由于美国推出的所谓“对等关税”严重超出市场预期,投资者对全球经济陷入衰退的担忧加剧。主要产油国5月起将增产,石油输出国组织(欧佩克)3日发表声明说,8个欧佩克和非欧佩克产油国决定自今年5月起日均增产41.1万桶。这一增产量远高于市场预期。(财联社)

2小时前

蔚来推“5年免费换电”+5年0息限时购车政策

36氪获悉, 4月4日,蔚来宣布,即日起至4月30日期间,用户支付定金购买蔚来ET5、ET5T、ES6、EC6、ET7、EC7、ES8车型,可获赠240张免费换电券(换电券5年有效)。新政策可与现有5年0息金融方案,最高10,000元换电车型专享补贴,以及3年NOP+免费使用权(价值13,680元)同享。此外,以旧换新用户还可享受最高15,000元汽车以旧换新补贴,以及各地消费补贴(以各地公布实施细则为准)。

2小时前

海南修订细则支持大型演唱会等演出,最高奖励300万元

日前,海南省旅文厅修订并印发《海南省关于支持大型演唱会、音乐节及高品质优秀剧目文艺演出实施细则》,明确符合相关奖励标准的大型演唱会、音乐节,将给予最高300万元一次性奖励。该细则自公布之日起施行,有效期至2025年12月31日,奖补申报时间截至2026年2月28日。(新浪财经)

2小时前

本页详细列出关于中生健康的品牌信息,含品牌所属公司介绍,中生健康所处行业的品牌地位及优势。
咨询